SURMOUNT-1 randomized 2,539 adults with overweight or obesity (without T2D) to tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight loss: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) vs 3.1% placebo. 91.0% of patients on 15 mg achieved ≥5% weight loss. Pivotal trial supporting Zepbound's FDA approval. NEJM 2022.
Also known as
SURMOUNT trial
Drugs in this category
Related terms
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist; active ingredient in Mounjaro and Zepbound.